2023 AUA Recaps : Episode 1

Video

AUA 2023: Dr. Stratton discusses prostate cancer research

Author(s):

Urology Times staff

Kelly L. Stratton, MD, FACS, recaps several presentations on prostate cancer from the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Kelly L. Stratton, MD, FACS, recaps several presentations from the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.

      The following research/presentations are discussed:

      1. Panel Discussion: Triple Therapy vs. Chemotherapy/ADT for Newly Diagnosed mHSPC Patients (Treatment intensification)

      2. MP29-01 (Saad et al): Rapid, durable, and deep prostate-specific antigen response following addition of darolutamide to androgen-deprviation therapy and docetaxel in ARASENS

      3. LBA02-09 (Shore et al): EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer

      4. Debate: Renaming Gleason 6 Prostate Cancer

      5. Advanced Prostate Cancer: AUA/SUO Guideline (2023)

      Related Videos
      Michael Cookson, MD, on challenges with PSMA-PET imaging
      Michael Cookson, MD, on challenges with PSMA-PET imaging
      Kelly L. Stratton, MD, FACS, answers a question during a Zoom video interview
      Dr. Stratton on noteworthy aspect of trial of relugolix and enzalutamide in high-risk prostate cancer
      Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
      Expert discusses trial evaluating relugolix and enzalutamide in high-risk prostate cancer
      Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
      Relugolix/enzalutamide trial to “bridge the gap” between STAMPEDE and PROTEUS trials
      Kelly L. Stratton, MD, FACS, answers a question during a Zoom video interview
      Dr. Stratton on phase 1B trial of relugolix and enzalutamide in high-risk prostate cancer
      AUA 2024: Dr. Smelser recaps key bladder cancer research
      AUA 2024: Dr. Smelser recaps key bladder cancer research
      Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
      AUA 2024: Dr. Cookson discusses prostate cancer research
      SUO 2023: Dr. Stratton previews prostate cancer research
      SUO 2023: Dr. Stratton previews prostate cancer research
      DNA molecules | Image Credit: © vitstudio - stock.adobe.com
      ctDNA in advanced bladder cancer: What does the future hold?
      Bradley Gill, MD, MS, answers a question during a Zoom video interview
      Dr. Bradley Gill on key BPH research from AUA 2023
      Related Content
      Medical cost concept with calculator and stethoscope | Image Credit: © thanksforbuying - stock.adobe.com
      January 11th 2025

      The economics of bladder cancer in the US: Increasing costs and unsustainable patterns

      Michael S. Cookson, MD, MMHC
      "The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      December 30th 2024

      Top 10 bladder cancer articles and videos of 2024

      Benjamin P. Saylor
      As the year comes to a close, we revisit some of this year’s top content on bladder cancer.
      Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
      September 26th 2024

      Prostate cancer management: Progress over 3 decades

      Michael S. Cookson, MD, MMHC
      "The landscape of prostate cancer management has evolved significantly over the past 30 years, with [active surveillance], advances in imaging and genetics, and improvements in the treatment of high-risk disease marking key areas of progress," writes Michael S. Cookson, MD, MMHC.
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      July 24th 2024

      Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer

      Urology Times staff
      "Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.
      Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
      April 5th 2024

      The management of high-risk localized prostate cancer: Back to the future

      Michael S. Cookson, MD, MMHC
      "I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.
      3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
      February 1st 2024

      BCG-unresponsive NMIBC: Advancements are finally moving the needle

      Michael S. Cookson, MD, MMHC
      "I predict 2024 will be a banner year for progress in the management of [NMIBC], and not only will we be moving the needle but also turning up the volume in this historically quiet space," writes Michael S. Cookson, MD, MMHC, FACS.
      © 2025 MJH Life Sciences

      All rights reserved.